- Home
- CCU vs GHRS Comparison
CCU vs GHRS Comparison
Compare CCU & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CCU | GHRS |
|---|---|---|
| Founded | 1850 | 2018 |
| Country | Chile | Ireland |
| Employees | N/A | N/A |
| Industry | Beverages (Production/Distribution) | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.0B |
| IPO Year | 2001 | 2021 |
Fundamental Metrics
Financial Performance| Metric | CCU | GHRS |
|---|---|---|
| Price | $10.68 | $18.85 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 7 | 10 |
| Target Price | $10.54 | ★ $42.89 |
| AVG Volume (30 Days) | 98.0K | ★ 269.9K |
| Earning Date | 11-03-2026 | 11-05-2026 |
| Dividend Yield | ★ 2.06% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $5.07 | N/A |
| Revenue Next Year | $4.83 | N/A |
| P/E Ratio | $18.35 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.25 | $12.04 |
| 52 Week High | $15.36 | $31.44 |
Technical Indicators
Market Signals| Indicator | CCU | GHRS |
|---|---|---|
| Relative Strength Index (RSI) | 40.17 | 22.99 |
| Support Level | $10.25 | $13.58 |
| Resistance Level | $12.15 | $25.30 |
| Average True Range (ATR) | 0.29 | 1.29 |
| MACD | 0.03 | -0.39 |
| Stochastic Oscillator | 42.38 | 6.78 |
Price Performance
Historical ComparisonAbout CCU Compania Cervecerias Unidas S.A.
United Breweries Co Inc is a multi-category beverage company with operations in Chile, Argentina, Bolivia, Colombia, Paraguay and Uruguay. The company is a player in each one of the beverage categories in which it participates in Chile, including beer, soft drinks, mineral and bottled water, juice, wine, cider and pisco, among others. The Company has three operating segment with respect to its revenues in the geographic areas of commercial activity: Chile; International business and Wine. It generates maximum revenue from Chile.
About GHRS GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.